Leap TherapeuticsLPTX
Market Cap: $106M
About: Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
Employees: 54
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
169% more call options, than puts
Call options by funds: $43K | Put options by funds: $16K
125% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 8
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
33% more capital invested
Capital invested by funds: $21.7M [Q1] → $28.7M (+$7.07M) [Q2]
6.5% more ownership
Funds ownership: 31.8% [Q1] → 38.3% (+6.5%) [Q2]
5% more funds holding
Funds holding: 43 [Q1] → 45 (+2) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 38 / 126 met price target | 99%upside $5.50 | Buy Reiterated | 13 Aug 2024 |
Rodman & Renshaw Tony Butler 100% 1-year accuracy 2 / 2 met price target | 190%upside $8 | Buy Initiated | 28 Jun 2024 |